Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05674487
Other study ID # CHUBX 2022/42
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 9, 2024
Est. completion date December 1, 2026

Study information

Verified date May 2024
Source University Hospital, Bordeaux
Contact Hanane Bouchghoul, MD
Phone +335 57 82 16 12
Email hanane.bouchghoul@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized trial is to compare two methods of induction in a fetal growth restriction population. The main question it aims to answer is: • Is trans-cervical balloon superior to prostaglandins in reducing the cesarean section rate, without increasing neonatal morbidity? Participants will have an induction of labour by cervical ripening with trans-cervical balloon in the trans-cervical balloon catheter arm and with Prostaglandins in the Misoprostol arm. Researchers will compare two methods of induction: trans-cervical balloon and prostaglandins to see if trans-cervical balloon is associated with a lower risk of cesarean delivery.


Description:

Fetal growth restriction (FGR) is associated with increased perinatal morbidity and mortality in late pregnancy. Because of this higher risk of adverse perinatal outcome, induction of labor is often proposed and require cervical ripening when the cervix is not favorable, i.e. Bishop score less than 6. Two methods of cervical ripening are currently available and used: pharmacological (prostaglandins) and mechanical (trans-cervical balloon). Growth-restricted fetuses are a population at increased risk for non-reassuring fetal status and hypoxia during labor because of their lower weight. Prostaglandins can lead to cardiotocograph (CTG) tracing abnormalities by causing uterine tachysystole in normal-weight fetuses. Nevertheless, the question of the method of induction of labor has been poorly studied in the population of growth-restricted fetuses. None of the national and international societies reports in their guidelines which method of induction of labor should be offered to pregnancies complicated by a fetal growth restriction. A few retrospective studies are in favor of an increased risk of uterine tachysystole with consequences on the CTG tracing in the case of cervical ripening with prostaglandins compared to the trans-cervical balloon. However, the results of these studies lack robustness due to important methodological limitations. Because trans-cervical balloon is a mechanical method of cervical ripening, it may be less likely to cause uterine tachysystole and thus fewer non-reassuring fetal status. Thus, the risk of cesarean section in labor could be decreased compared with the use of prostaglandins in the growth-restricted fetal population. To date, there is no published quality randomized controlled trials on the optimal method of cervical ripening in induction of labor for FGR fetuses. The present large-scale randomized trial aim to define the preferred method of induction for these fetuses, associated with a lower risk of cesarean delivery. If it is demonstrated that one method of induction (trans-cervical balloon) is superior to another (prostaglandins) in reducing the cesarean section rate, without increasing neonatal morbidity, the results of our study are likely to lead to changes in national and international recommendations.


Other known NCT identifiers
  • NCT05848869

Recruitment information / eligibility

Status Recruiting
Enrollment 774
Est. completion date December 1, 2026
Est. primary completion date December 1, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age over 18 years - Singleton gestation, with cephalic presentation - Gestational age at randomization between entre 34 weeks of gestation and 0 day and 41 weeks of gestation and 0 day - Fetal growth restriction (FGR). FGR is defined at the third trimester by an abdominal circumference below the 10th centile and/or an estimated fetal weight below the 10th centile (according to local curve), according to the trial DIGITAT. Fetus with normal and abnormal Doppler index can be included. - Plan for induction of labor whatever the indication (fetal growth restriction or other), the induction of labor is the induction of birth by vaginal delivery - Bishop Score below 6 - Affiliated or beneficiary to a health security system - Signed informed consent Exclusion Criteria: - Contraindication to an induction of labor - History of previous cesarean delivery, myomectomy by laparotomy or laparoscopy - Contraindication to misoprostol or trans-cervical balloon - Known HIV positivity (because of modified delivery plan) - Known major fetal anomaly or chromosomic anomaly - Fetal demise - Patient under legal protection - Poor understanding of the French language

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Trans-cervical balloon
Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
Drug:
Misoprostol
Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)

Locations

Country Name City State
France CHU Bordeaux Bordeaux

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Bordeaux French Ministry of Social Affairs and Health

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary cesarean section Incidence of cesarean section defined as a cesarean birth regardless of the indication Day 1
Secondary duration of labor Mean duration of labor (duration between admission to the labor room and delivery) Day 1
Secondary duration between cervical ripening and delivery Mean duration between cervical ripening and delivery Day 1
Secondary oxytocin use Incidence of oxytocin use (median of the maximal administered dosage) Day 1
Secondary operative delivery Incidence of operative delivery (vacuum, forceps, spatula) Day 1
Secondary postpartum hemorrhage Incidence of postpartum hemorrhage defined by blood loss >500mL (defined according to the CNGOF criteria) Day 3
Secondary Mean total blood loss Mean total blood loss (mL) Day 3
Secondary intra-uterine infectious Incidence of intra-uterine infectious defined by a fever (maternal temperature equal to or greater than 38°C twice), associated to at least one of the two criterion: persistent fetal tachycardia > 160 bpm, or purulent amniotic fluid (defined according to the CNGOF criteria). Day 5
Secondary iron administration Incidence of postpartum intravenous iron administration Day 5
Secondary transfusion Incidence of transfusion of blood products or blood Day 5
Secondary maternal thromboembolism event Incidence of maternal thromboembolism event (deep venous thrombosis diagnosed using leg Doppler ultrasound or pulmonary embolism diagnosed using computed tomographic pulmonary angiography) Day 5
Secondary maternal satisfaction Incidence of maternal satisfaction with a satisfaction questionnaire derived from the childbirth experience questionnaire and satisfaction questionnaire of TRAAP2 study Day 5
Secondary Mean duration of hospitalization Mean duration of hospitalization Day 5
Secondary umbilical artery lactic acid Incidence of umbilical artery lactic acid greater than 10mmol/l Day 1
Secondary umbilical artery pH Incidence of umbilical artery pH of less than 7,05 Day 1
Secondary neonatal Apgar Score Incidence of neonatal 5 minutes Apgar Score of less than 7 Day 1
Secondary neonatal hypoglycemia Incidence of neonatal hypoglycemia (blood glucose < 35 mg/L) requiring intravenous therapy Day 5
Secondary neonatal intensive care Incidence of admission to neonatal intensive care unit or intermediate care unit Day 5
Secondary neonatal length of hospital stay Mean neonatal length of hospital stay Day 5 up to Month 2
Secondary neonatal death before discharge Incidence of neonatal death before discharge Day 1 up to Month 2
Secondary non-reassuring fetal status Incidence of non-reassuring fetal status occurring after the beginning of the cervical ripening (including both cervical ripening and labor). Non-reassuring fetal status is defined by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO), who class the CTG tracing in 3 class: normal, suspicious and pathological 3. According to this classification, non-reassuring fetal status is defined as the presence of a suspicious or pathological CTG tracings, predictive of hypoxia/ neonatal acidosis status Day 1
Secondary cesarean section for non-reassuring fetal status Incidence of cesarean section for non-reassuring fetal status Day 1
Secondary cesarean section for arrest of labor Incidence of cesarean section for arrest of labor Day 1
Secondary neonatal ventilation Incidence of the need for neonatal ventilation in the first 72 hours of life, defined by intubation, continuous positive airway pressure (CPAP) or high-flow nasal cannula Day 3
Secondary neonatal hypoxic-ischemic encephalopathy Incidence of neonatal hypoxic-ischemic encephalopathy Day 1 up to Month 2
Secondary neonatal seizure Incidence of neonatal seizure Day 1
Secondary neonatal infection Incidence of neonatal infection (confirmed sepsis or pneumonia) Day 1 up to Day 28
Secondary neonatal meconium aspiration syndrome Incidence of neonatal meconium aspiration syndrome, Day 5
Secondary birth trauma Incidence of birth trauma (bone fracture, neurologic injury, or retinal hemorrhage), Day 5
Secondary neonatal intracranial or subgaleal hemorrhage Incidence of neonatal intracranial or subgaleal hemorrhage, Day 5
Secondary neonatal arterial hypotensio Incidence of neonatal arterial hypotension requiring pressor support day 1
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Recruiting NCT05601375 - Speckle Tracking Echocardiography in Infants, Prenatally and Postnatally
Recruiting NCT03662178 - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Completed NCT05059093 - Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
Completed NCT03067298 - Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening
Recruiting NCT01981824 - Prediction of Growth Restricted Fetuses Using Femur Length to Mid-thigh Circumference Ratio: A Case-control Study N/A
Recruiting NCT04215107 - Fetal Distribution of Feto-placental Blood Flow Related to Placental Nutrient Transport and Maternal Food Intake N/A
Completed NCT02189148 - First-trimester Prediction of Preeclampsia
Terminated NCT04084990 - Sleep Apnea and Fetal Growth Restriction Phase 3
Recruiting NCT04051567 - Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies Phase 4
Recruiting NCT04394611 - Metals and in Fetal Growth Restriction
Completed NCT01369940 - The NICHD Fetal Growth Study: Twin Gestations N/A
Not yet recruiting NCT03121196 - Social Deprivation and Pregnancy N/A
Recruiting NCT03177824 - Sildenafil Citrate for Treatment of Growth-restricted Fetuses Phase 3
Completed NCT02379832 - Pre-Eclampsia And Growth Restriction: a Longitudinal Study
Completed NCT02379494 - First Trimester Prediction of Preeclampsia and Fetal Growth Restriction N/A
Completed NCT03046355 - Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women N/A
Not yet recruiting NCT05848869 - Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction N/A
Recruiting NCT04438668 - Evaluation of the Safety and Performance of Centaflow N/A
Recruiting NCT05423665 - Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies